ID   WSU-CLL
AC   CVCL_A049
DR   BioSample; SAMN03151907
DR   cancercelllines; CVCL_A049
DR   Wikidata; Q29958010
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8558918;
RX   PubMed=12200708;
RX   PubMed=12592342;
RX   PubMed=20143388;
RX   PubMed=24923861;
WW   https://iclac.org/education/wsu-cll/
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a Reh derivative (PubMed=12200708; PubMed=12592342; PubMed=20143388; PubMed=24923861). Originally thought to originate from a 68 year old male patient with chronic lymphocytic leukemia.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00285.
CC   Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   NCIt; C80334; B lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1) ETV6-RUNX1
DI   ORDO; Orphanet_585929; B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1650 ! Reh
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 28
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8558918;
RA   Mohammad R.M., Mohamed A.N., Hamdan M.Y., Vo T., Chen B., Katato K.,
RA   Abubakr Y.A., Dugan M.C., Al-Katib A.;
RT   "Establishment of a human B-CLL xenograft model: utility as a
RT   preclinical therapeutic model.";
RL   Leukemia 10:130-137(1996).
//
RX   PubMed=12200708; DOI=10.1038/sj.leu.2402610;
RA   Drexler H.G., Quentmeier H., Dirks W.G., Uphoff C.C., MacLeod R.A.F.;
RT   "DNA profiling and cytogenetic analysis of cell line WSU-CLL reveal
RT   cross-contamination with cell line REH (pre B-ALL).";
RL   Leukemia 16:1868-1870(2002).
//
RX   PubMed=12592342; DOI=10.1038/sj.leu.2402799;
RA   Drexler H.G., Dirks W.G., Matsuo Y., MacLeod R.A.F.;
RT   "False leukemia-lymphoma cell lines: an update on over 500 cell
RT   lines.";
RL   Leukemia 17:416-426(2003).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=24923861; DOI=10.1016/j.leukres.2014.05.003;
RG   International Cell Line Authentication Committee (ICLAC);
RT   "Cell line cross-contamination: WSU-CLL is a known derivative of REH
RT   and is unsuitable as a model for chronic lymphocytic leukaemia.";
RL   Leuk. Res. 38:999-1001(2014).
//